Physician profile
Muhammad Idrees
NPI 1720430127
$1,495.83
in general payments reported to CMS, 2019-2025
11 companies · $283 in 2025
The $283 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $23.48 · 2021: $139 · 2022: $403 · 2023: $309 · 2024: $338 · 2025: $283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $930.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $930.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $526.94 | 2022-2025 | Qelbree, Qelbree |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $412.90 | 2021-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $298.86 | 2021-2023 | Xarelto |
| Bioxcel Therapeutics, INC. | $63.14 | 2023 | Igalmi |
| Novartis Pharmaceuticals Corporation | $44.90 | 2022-2024 | |
| Smith+Nephew, INC. | $38.40 | 2023 | Regranex, Collagenase Santyl |
| Lexicon Pharmaceuticals, INC. | $34.10 | 2023 | Inpefa |
| Noven Therapeutics, LLC | $23.48 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.32 | 2023 | Xifaxan |
| Astrazeneca Pharmaceuticals Lp | $18.56 | 2022 | |
| Pfizer INC. | $11.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Idrees listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.